Osanetant - Novel Investigational Agent for the Treatment of Schizophrenia

Print-Icon
Print

Affecting around 1% of the general population, schizophrenia is a severe and debilitating mental illness. (Source: ABPI)
 
Next»

Return to Project




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development